Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of HKI-272 [neratinib] administered orally to subjects with HER-2/NEU or HER-1/EGFR [epidermal growth factor receptor]-positive tumors

Trial Profile

An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of HKI-272 [neratinib] administered orally to subjects with HER-2/NEU or HER-1/EGFR [epidermal growth factor receptor]-positive tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Sep 2018

At a glance

  • Drugs Neratinib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Puma Biotechnology
  • Most Recent Events

    • 11 May 2012 Additional company (Puma Biotechnology) added in association as reported by ClinicalTrials.gov.
    • 04 Dec 2007 Status changed from in progress to completed as reported on clinicaltrials.gov website.
    • 07 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top